Abstracts from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition provided new insight into multiple treatments for patients with multiple myeloma (MM), chronic lymphocytic ...

Access to and outcomes of chimeric antigen receptor (CAR) T-cell therapies may differ by characteristics such as race, ethnicity, gender, and geographic location among patients with cancer. Access to ...

- CRG-023 is a CD19-, CD20-, CD22-targeting tri-specific CAR T product candidate designed with the goal of providing more patients with a broad range of B-cell malignancies with durable responses by ...

As a hematologist with a keen interest in multiple myeloma who’s looking forward to the 2025 American Society of Hematology (ASH) Annual Meeting and Exposition in December, I’ve picked out this list ...

(WASHINGTON, November 7, 2019) - The American Society of Hematology (ASH) is pleased to recognize the following trainees, whose meritorious scientific abstract has received one of the awards in the ...

Oral presentation of investigator-initiated Phase 2 study evaluating ZYNLONTA ® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with r/r follicular lymphoma Poster presentation ...